SCHEMBL7359462

SCHEMBL7359462

C[C@@H](O)[C@@H](CC1CCC(c2ccccc2)CC1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.42
KCNH2 Q12809 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
TDO2 P48775 1/20 0.41
AKR1C3 P42330 1/20 0.41
AKR1C1 Q04828 1/20 0.41
SLC18A3 Q16572 4/20 0.40
SIGMAR1 Q99720 1/20 0.40
PRCP P42785 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
OPRM1 P35372 1/20 0.38
LIPG Q9Y5X9 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7876535 0.80 IDO1 (0.39) IDO1KCNH2HRH3TDO2AKR1C3
SCHEMBL5762361 0.76 SLC18A3 (0.44) IDO1KCNH2HRH3AKR1C3AKR1C1
SCHEMBL24663869 0.74 IDO1 (0.51) IDO1KCNH2HRH3AKR1C3AKR1C1
SCHEMBL5762356 0.72 ALDH1A1 (0.44) IDO1SLC18A3KDM4EALDH1A1
SCHEMBL14379232 0.71 KCNH2 (0.48) KCNH2HRH3AKR1C3AKR1C1SLC18A3
SCHEMBL20838768 0.71 KCNH2 (0.48) KCNH2HRH3AKR1C3AKR1C1SLC18A3
SCHEMBL14379229 0.71 KCNH2 (0.48) KCNH2HRH3AKR1C3AKR1C1SLC18A3
SCHEMBL17025330 0.71 KCNH2 (0.48) KCNH2HRH3AKR1C3AKR1C1SLC18A3
SCHEMBL10994596 0.71 IDO1 (0.41) IDO1KCNH2HRH3TDO2SLC18A3
Bicarbonate SCHEMBL1720488 0.71 AKR1C3 (0.63) IDO1KCNH2HRH3AKR1C3AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6329400-B1 INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS GLAXO WELLCOME INC. 2001-12-11 US disclosed
WO-2000012082-A1 FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS GLAXO GROUP LIMITED (GB) 2000-03-09 WO disclosed